Refine by
Cancer Risk Articles & Analysis
91 news found
Forever chemicals – also known as per and poly fluoralkyl substances (PFAS) – are a family of different compounds so called because of how they persist in the environment, with many (such as perfluorooctanoic acid and perfluorooctane sulfonic acid) associated with adverse effects in both animals and people. PFAS enjoy widespread use in a range of different industries, featuring in ...
Some of these same carcinogens could even be an exposure risk for anyone entering a building or worksite. In the United States, the Centers for Disease Control and Prevention (CDC) reports that more men and women die in this country from lung cancer than from any other type of cancer. This correlates to approximately 136,000 annual deaths and ...
” Now hospitals can use the technology while we learn more about the long term (>10 years) outcomes of using the NanoKnife System for prostate cancer as they collect their audit data. When men are diagnosed with prostate cancer it is graded as Low, Intermediate or High risk. As documented in the NICE guidance, Low risk ...
We are pleased to offer congratulations to Professor Jurgen Fütterer and his team at Radboud University Medical Centre in the Netherlands, for having successfully secured €3.8 million from the Dutch National Health Care Institute and ZonMw towards the ENFORCE trial, a fully funded Randomised Controled Trial for Focal Therapy which incorporates the NanoKnife System as a treatment option ...
For men, it is the second-most diagnosed cancer globally after lung cancer. Advanced age, ethnicity, obesity and family history are known risk factors. ...
The lung cancer screening demonstration project led by Dr Simon Martel, pulmonologist at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie de Québec-Université Laval – IUCPQ-UL) is intended to combine BioMark’s metabolomics liquid biopsy test with radiomics and genetics biomarkers to help at-risk ...
” The product labels of all JAK inhibitors will be updated to include a precautionary approach for patients aged 65 years or above, those at increased risk of major cardiovascular problems (such as heart attack or stroke), those who smoke or have done so for a long time in the past and those at increased risk of cancer. For those ...
Developed by specialists from the medical, technology, and design fields, the platform aims to establish a culture of preventative healthcare in Latvia as well as educate women on breast cancer risks and contraception methods. By educating more individuals and collecting real-world data, skrinings.lv is actively contributing to decreasing unwanted pregnancies, ...
Results from this trial were published in the New England Journal of Medicine.1 The ARASENS trial demonstrated that darolutamide plus ADT and docetaxel significantly reduced the risk of death by 32.5% compared to ADT plus docetaxel.1 Improvements in the secondary endpoints supported the OS benefit observed in the trial’s primary endpoint.1 About Metastatic ...
ByBayer AG
The miR Sentinel™ Test assesses the risk of aggressive prostate cancer and is intended to aid in the detection and clinical management of men >45 years of age at risk for prostate cancer. "An estimated 268,490 men will be diagnosed with prostate cancer in 2022 according to the American ...
Darolutamide is approved in more than 70 markets around the world, including the U.S., the European Union (EU), Japan and China, under the brand name Nubeqa™, for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease. ...
ByBayer AG
In developing QVCAD algorithms for 3D ABUS, it collected ABUS cancer cases from sites worldwide that represent over one million ABUS 3D images. ...
Skrinings.lv also offers a breast cancer risk assessment tool in Russian, English and Latvian that has helped more than 8000 people take more control over their breast health and prevent devastating late-stage diagnoses. ...
The miR Sentinel™ Test assesses the risk of aggressive prostate cancer and is intended to aid in the clinical management of men >45 years of age at risk for prostate cancer. ...
"We are excited to announce the accomplishment of this important milestone in our path to demonstrate the potential of C-Scan to detect colorectal polyps before they may turn into cancer in the average-risk population," said Alex Ovadia, chief executive officer of Check-Cap. ...
Darolutamide is already approved in more than 60 markets around the world, including the U.S., the European Union (EU), Japan and China, under the brand name Nubeqa™, for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease. ...
ByBayer AG
(Nasdaq: GH), a leading precision oncology company, today announced the availability of Shield™, the company’s first blood-based test for the detection of early-stage colorectal cancer (CRC). The test, which only requires patients to complete a simple blood draw, is intended for adults age 45 and older who are not up to date with recommended screening guidelines, show ...
Scientific Presentation: Cryoablation of Low-Risk Breast Cancer An Update of the ICE3 Trial Dr. Kenneth R. Tomkovich, Co-Primary Investigator of the ICE3 trial, presented promising interim data on cryoablation of small, low-risk breast cancers on April 26. ...
The meeting includes state-of-the-art translational topics on prostate, kidney, and bladder cancer, as well as strategies in urologic oncology will be discussed. ...
The published article on the study, Treatment of intermediate-risk prostate cancer with Cs-131: Long-term results from a single institution, was authored by Joshua L. ...